On day 2 of the Community Oncology Alliance's annual Community Oncology Conference, held April 4-5 in Orlando, Florida, we spoke with Debra Patt, MD, MPH, MBA, executive vice president of Texas Oncology, and Jeffrey Vacirca, MD, chief executive officer of New York Cancer & Blood Specialists.
Today, we are on site for day 2 of the Community Oncology Alliance’s annual Community Oncology Conference in Orlando, Florida!
We will be recapping some of the top news presented each day during the meeting—and soon we’ll speak with Debra Patt, MD, vice president of Texas Oncology, and Jeff Vacirca, MD, of New York Cancer & Blood Specialists.
Welcome to AJMC® on location, I’m Jaime Rosenberg!
The second day of the meeting focused on cancer drugs and different strategies for addressing their cost. There was a session on chimeric antigen receptor T-cell therapy, which explored different clinical and reimbursement challenges associated with the treatment. In addition, there were sessions on the adverse impact pharmacy benefit managers have on cancer care, and the effect of step therapy and utilization management on access to cancer treatments. We also got an industry perspective on price, cost, and value of cancer drugs.
Read coverage and watch additional interviews.
That’s all from COA's Annual Community Oncology Conference. Join us again May 19-21, when we will be reporting on site at The International Society for Pharmacoeconomics and Outcomes Research’s annual meeting being held in New Orleans, Louisiana.
Thank you for watching AJMC® News Network! I’m Jaime Rosenberg.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More